Skip to main content
. 2021 Oct 28;6:128. doi: 10.1038/s41541-021-00393-6

Fig. 2. Overview of SARS-CoV-2 RBD cross-neutralizing antigenic sites.

Fig. 2

Center panel: composite model of the SARS-CoV-2 S-protein trimer (gray) with four distinct monoclonal antibodies (S2E12 in purple, S2X259 in red, S2H97 in green, and S309 in blue) bound to one RBD in the open conformation. Top and bottom, left and right panels: magnified model of RBD (gray) with the ACE2-binding site outlined in black and the respective mAb cognate epitopes indicated by color. In dark blue is a surface representation of the glycan at position N343, which is conserved across the sarbecovirus subgenus. Top left: antigenic site Ia (purple) is targeted by the S2E12 mAb, which neutralizes the VOC and clade 1b, SARS-CoV-2-related, sarbecoviruses29. Bottom left: antigenic site IIa (red) is targeted by the S2X259 mAb, which inhibits ACE2 binding, neutralizes the VOC and clades 1a&b SARS-CoV-2-related sarbecoviruses, and binds to clades 2/3 sarbecoviruses30. Bottom right: antigenic site IV (blue) is targeted by the S309 mAb, which neutralizes the VOC and clades 1a&b SARS-CoV-2-related sarbecoviruses27,35. Top right: antigenic site V (green) is targeted by S2H97, which neutralizes the VOC and clades 1a&b SARS-CoV-2-related sarbecoviruses, and binds to clades 2/3 sarbecoviruses34.